Ramsay Stattman Vela & Price Inc. Sells 190 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ramsay Stattman Vela & Price Inc. trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,039 shares of the medical equipment provider’s stock after selling 190 shares during the period. Ramsay Stattman Vela & Price Inc.’s holdings in Zimmer Biomet were worth $1,166,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Exchange Traded Concepts LLC raised its position in shares of Zimmer Biomet by 3,043.1% during the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock worth $173,000 after acquiring an additional 1,552 shares during the last quarter. NBC Securities Inc. acquired a new stake in Zimmer Biomet during the 3rd quarter worth $105,000. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Zimmer Biomet by 1.5% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,230 shares of the medical equipment provider’s stock valued at $2,400,000 after acquiring an additional 337 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Zimmer Biomet by 165.3% in the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock valued at $187,000 after purchasing an additional 1,071 shares during the period. Finally, Border to Coast Pensions Partnership Ltd increased its holdings in Zimmer Biomet by 4.5% in the third quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock valued at $16,711,000 after purchasing an additional 6,623 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ZBH shares. Wells Fargo & Company upped their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Barclays decreased their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Truist Financial reiterated a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Up 0.6 %

NYSE ZBH opened at $100.52 on Tuesday. The stock’s 50-day simple moving average is $106.34 and its two-hundred day simple moving average is $107.67. The company has a market capitalization of $20.01 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company posted $2.20 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.